aTyr Pharma (ATYR) vs Context Therapeutics (CNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Context Therapeutics (CNTX) has outperformed aTyr Pharma (ATYR) over the past year, losing 73.8% versus a loss of 74.5%. Context Therapeutics is the larger company by market cap ($27.5 million vs $25.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | CNTX |
|---|---|---|
| Share price | $0.2553 | $0.299 |
| Market cap | $25.04M | $27.47M |
| 1-day change | -8.26% | -4.35% |
| YTD return | -67.39% | -79.66% |
| 1-year return | -74.47% | -73.77% |
| 5-year return | -97.07% | — |
| EPS (TTM) | $-0.62 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $3.62 |
| 52-week low | $0.25 | $0.295 |
| Distance from 52-week high | -77.21% | -91.74% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1020.25% | +1247.83% |
| Average volume | 3.24M | 1.66M |
| Shares outstanding | 98.09M | 91.88M |
| Employees | 58 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Healthcare · Biotechnology · 58 employees
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Healthcare · Biotechnology · 15 employees
ATYR vs CNTX FAQ
Which is bigger, aTyr Pharma or Context Therapeutics?
Context Therapeutics (CNTX) is larger, with a market capitalization of $27.47M compared with $25.04M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ATYR or CNTX?
CNTX returned -73.77% over the past 12 months, compared with -74.47% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Context Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.